http://acomplia.drugspill.com All about Acomplia online Tue, 07 Apr 2009 21:04:53 +0000 http://backend.userland.com/rss092 en The UK National Institute for Health and Clinical Excellence (NICE) has approved the use of anti-obesity drug Acomplia (Rimonabant). The green light was given after the medication received positive appraisal from the institute in March. Acomplia is recommended as an addition to exercise and proper diet for obese and overweight patients ... http://acomplia.drugspill.com/acomplia-finally-gets-ok-for-the-uk/ The manufacturer of Acomplia (rimonabant) Sanofi-Aventis reported that according to the findings of a recent medical trial the drug significantly improved glucose control in patients diagnosed with type 2 diabetes. The 11-month trial called ARPEGIO involved 368 patients with type 2 diabetes who had been treated with standard insulin-diet-exercise therapies for ... http://acomplia.drugspill.com/acomplia-improves-glucose-control/ Sanofi-Aventis said a trial of its Acomplia drug involving patients with type 2 diabetes showed a significant improvement in glucose control compared to insulin. The company said glucose control was three times more pronounced when rimonabant - the generic name for Acomplia - was used rather than insulin and lifestyle advice ... http://acomplia.drugspill.com/acomplia-improved-glucose-control-for-type-2-diabetes/ According to the data provided by the Decision Resources Research company, the market of anti-obesity medications and therapies is likely to grow five times by the year 2016. The company’s analysts anticipate that the market worth approximately $478 million 2 years ago will reach almost $3 billion within the next 8 ... http://acomplia.drugspill.com/obesity-market-growing/ Computed Axial Tomography (Cat) scans of patients taking Acomplia (Rimonabant) have proved that the drug is effective in treating dangerous abdominal obesity which is known to cause diabetes. An international study of Rimonabant in abdominally obese patients sponsored by Sanofi-Aventis confirmed that the diet drug can significantly reduce visceral fat and ... http://acomplia.drugspill.com/acomplia-rimonabant-proved-effective-by-computed-axial-tomography-scans/ Acomplia (Rimonabant) Manufacturer: Sanofi-Aventis Acomplia (rimobant) is a weight-loss medicine. It is marketed under the brand names Acomplia in Europe and Zimulti in the USA. There is also a generic version of this drug called Rimonabant. Although Acomplia has been approved for marketing throughout Europe, it is still undergoing the process of ... http://acomplia.drugspill.com/acomplia-rimonabant/ Marc Cluzel, Sanofi's head of research, said in a round of interviews in London that he continues to believe Acomplia can be a winner. Sanofi-Aventis said on April 3rd it still has high hopes for diet drug rimonabant (Acomplia / Zimulti), even though it was rejected by a U.S. FDA advisory ... http://acomplia.drugspill.com/winner-by-sanofi/ With sales of Acomplia (rimonabant) lagging in the several dozen countries where it is on the market, Sanofi-Aventis executives had little to say about their pioneering obesity treatment in a report to analysts on Feb. 12th. But that hardly means they have given up on the CB-1 receptor antagonist. Instead, Sanofi ... http://acomplia.drugspill.com/sales-of-acomplia/ Merck & Co.s experimental diet pill, developed using research on marijuana, may curb the munchies and lead to weight loss, a study says.Patients taking the pill, taranabant, lost an average of 6 to 12 pounds, depending on dose. Those given a placebo lost about 3 pounds during the 12-week study, ... http://acomplia.drugspill.com/merck-pill-derived-from-pot-research-curbs/ Sanofi-Aventis  said on Tuesday the European Commission had endorsed the positive opinion of the European Medicines Evaluation Agency (EMEA) for its anti-obesity drug Acomplia (rimonabant) to include type 2 diabetes trial results into the European label (section 5.1). The update is based on the results of the SERENADE study, which ... http://acomplia.drugspill.com/acomplia-pill-ec-endorses-positive-opinion/